Skip to Content

Arcturus Therapeutics Holdings Inc - Stock Quote ARCT

Rating as of

Morningstar's Arcturus Therapeutics Holdings Inc Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Arcturus Therapeutics Holdings Inc's Company Profile

Business Description

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.

Contact
10628 Science Center Drive, Suite 250
San Diego, CA, 92121
T +1 858 900-2660
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type Distressed
Employees 177